Point72 Asia Singapore Pte. Ltd. Invests $64,000 in Marinus Pharmaceuticals, Inc. (NASDAQ:MRNS)

Point72 Asia Singapore Pte. Ltd. purchased a new position in Marinus Pharmaceuticals, Inc. (NASDAQ:MRNS) in the 2nd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The fund purchased 54,878 shares of the biopharmaceutical company’s stock, valued at approximately $64,000. Point72 Asia Singapore Pte. Ltd. owned approximately 0.10% of Marinus Pharmaceuticals at the end of the most recent quarter.

Other large investors have also recently made changes to their positions in the company. Point72 DIFC Ltd purchased a new position in Marinus Pharmaceuticals during the 2nd quarter worth $28,000. SG Americas Securities LLC purchased a new stake in Marinus Pharmaceuticals during the 2nd quarter valued at about $34,000. AQR Capital Management LLC grew its stake in Marinus Pharmaceuticals by 70.3% during the 2nd quarter. AQR Capital Management LLC now owns 31,333 shares of the biopharmaceutical company’s stock valued at $37,000 after purchasing an additional 12,934 shares during the last quarter. Jacobs Levy Equity Management Inc. purchased a new stake in Marinus Pharmaceuticals during the 1st quarter valued at about $384,000. Finally, Values First Advisors Inc. grew its stake in Marinus Pharmaceuticals by 501.8% during the 2nd quarter. Values First Advisors Inc. now owns 62,671 shares of the biopharmaceutical company’s stock valued at $73,000 after purchasing an additional 52,257 shares during the last quarter. 98.80% of the stock is owned by institutional investors.

Marinus Pharmaceuticals Price Performance

Shares of Marinus Pharmaceuticals stock opened at $1.78 on Friday. Marinus Pharmaceuticals, Inc. has a 12 month low of $1.05 and a 12 month high of $11.26. The company has a debt-to-equity ratio of 5.68, a current ratio of 2.28 and a quick ratio of 2.15. The stock has a market capitalization of $97.78 million, a P/E ratio of -0.67 and a beta of 1.14. The business has a 50 day simple moving average of $1.44 and a two-hundred day simple moving average of $2.31.

Marinus Pharmaceuticals (NASDAQ:MRNS) last posted its quarterly earnings results on Tuesday, August 13th. The biopharmaceutical company reported ($0.60) EPS for the quarter, missing the consensus estimate of ($0.59) by ($0.01). Marinus Pharmaceuticals had a negative net margin of 493.14% and a negative return on equity of 7,831.35%. The company had revenue of $8.06 million during the quarter, compared to analyst estimates of $9.05 million. During the same period in the prior year, the business posted ($0.61) EPS. As a group, analysts predict that Marinus Pharmaceuticals, Inc. will post -1.88 EPS for the current fiscal year.

Wall Street Analysts Forecast Growth

A number of analysts have recently commented on MRNS shares. Oppenheimer upgraded Marinus Pharmaceuticals from a “market perform” rating to an “outperform” rating and set a $6.00 target price on the stock in a research note on Monday, September 23rd. Cantor Fitzgerald reaffirmed an “overweight” rating and issued a $13.00 price target on shares of Marinus Pharmaceuticals in a report on Tuesday, September 24th. EF Hutton Acquisition Co. I raised Marinus Pharmaceuticals to a “strong-buy” rating in a report on Monday, September 30th. HC Wainwright reaffirmed a “buy” rating and issued a $11.00 price target on shares of Marinus Pharmaceuticals in a report on Wednesday, August 14th. Finally, JMP Securities reissued a “market outperform” rating and set a $10.00 target price on shares of Marinus Pharmaceuticals in a report on Monday, September 23rd. Four research analysts have rated the stock with a hold rating, five have assigned a buy rating and one has given a strong buy rating to the company’s stock. According to MarketBeat, Marinus Pharmaceuticals has a consensus rating of “Moderate Buy” and an average target price of $8.83.

Marinus Pharmaceuticals Profile

Marinus Pharmaceuticals, Inc, a pharmaceutical company, focuses on development and commercialization of therapeutic products for patients suffering from rare genetic epilepsies and other seizure disorders. It offers ZTALMY (ganaxolone), an oral suspension for the treatment of seizures associated with cyclin-dependent kinase-like 5 deficiency disorder for adult and pediatric patient populations in acute and chronic care, and in-patient and self-administered settings.